The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $5.19

Today's change+0.03 +0.58%
Updated May 27 4:00 PM EDT. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $5.19

Today's change+0.03 +0.58%
Updated May 27 4:00 PM EDT. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc up (U.S.)$0.03

Infinity Pharmaceuticals Inc closed up Friday by (U.S.)$0.03 or 0.58% to (U.S.)$5.19. Over the last five days, shares have gained 7.45%, but are down 33.89% for the last year to date. Shares have underperformed the S&P 500 by 59.29% during the last year.

Key company metrics

  • Open(U.S.) $5.16
  • Previous close(U.S.) $5.16
  • High(U.S.) $5.23
  • Low(U.S.) $4.97
  • Bid / Ask(U.S.) $5.12 / (U.S.) $8.31
  • YTD % change-33.89%
  • Volume138,055
  • Average volume (10-day)353,084
  • Average volume (1-month)375,628
  • Average volume (3-month)572,156
  • 52-week range(U.S.) $4.50 to (U.S.) $13.32
  • Beta1.49
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.52
Updated May 27 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-66.46%

Although this company's net profit margin is negative, it is above the industry average and implies that Infinity Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.22%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue99915
Total other revenue--------
Total revenue99915
Gross profit--------
Total cost of revenue--------
Total operating expense50484743
Selling / general / administrative119109
Research & development39393834
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-41-3943-39
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-41-3943-38
Income after tax-41-3943-38
Income tax, total--00--
Net income-41-3943-38
Total adjustments to net income-----1--
Net income before extra. items-41-3943-38
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-41-3942-38
Inc. avail. to common incl. extra. items-41-3942-38
Diluted net income-41-3942-38
Dilution adjustment----0--
Diluted weighted average shares49495049
Diluted EPS excluding extraordinary itemsvalue per share-0.82-0.800.84-0.78
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.82-0.800.84-0.78
R